PREVENTION OF HEPATITIS B RECURRENCE IN LIVER TRANSPLANT PATIENTS USING ORAL ANTIVIRAL THERAPY WITHOUT LONG-TERM HEPATITIS B IMMUNOGLOBU-LIN

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

AHN JOSEPH; COHEN STANLEY MARTIN

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2011 | Volume:11 | Issue:8 (37) Page(s): 638-645

Download Full-Text

View:

373

Download:

329

Cites:

Information Journal Paper

Title

PREVENTION OF HEPATITIS B RECURRENCE IN LIVER TRANSPLANT PATIENTS USING ORAL ANTIVIRAL THERAPY WITHOUT LONG-TERM HEPATITIS B IMMUNOGLOBU-LIN

Author(s)

AHN JOSEPH | COHEN STANLEY MARTIN | Issue Writer Certificate

Keywords

HEPATITIS B

LIVER TRANSPLANTATION

IMMUNOGLOBULIN

Abstract

Background: Small studies have suggested that nucleos (t) ide analogue therapy (NAT) with reduced HEPATITIS B IMMUNOGLOBULIN (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. This larger study evaluates the use of NAT with short term (<6 mo) or no HBIG for prevention of post-LT HBV recurrence.Patients and Methods: All HBV patients undergoing LT at a university transplant center between 2002 and 2007 were identified retrospectively. Patient demographics, medication regimen, and adverse events were noted. The primary endpoint was HBV recurrence and secondary endpoints were graft and patient survival.Results: 28 study patients were identified. Of these 28 patients, 4 (14%) received no HBIG, 6 (22%) received only inpatient HBIG, and 18 (64%) received inpatient HBIG and outpatient HBIG.16 of the 28 patients (57%) received combination NAT and 12 patients (43%) received single NAT. At a median time of 15.5 months (range 9–24 months) post- LT, 4 of the 28 patients (14%) had recurrent HBV. Of those patients with recurrent HBV, 3 received both inpatient and outpatient HBIG and 1 received no HBIG. All cases of HBV recurrence were associated with noncompliance.Conclusions: NAT with short-term or no HBIG was efficacious and safe in preventing post-LT HBV. All compliant patients were HBV-free, including 9 patients who received no HBIG or only inpatient HBIG. Additional studies using NAT without HBIG appear justified.

Cites

No record.

References

No record.

Cite

APA: Copy

AHN, JOSEPH, & COHEN, STANLEY MARTIN. (2011). PREVENTION OF HEPATITIS B RECURRENCE IN LIVER TRANSPLANT PATIENTS USING ORAL ANTIVIRAL THERAPY WITHOUT LONG-TERM HEPATITIS B IMMUNOGLOBU-LIN. HEPATITIS MONTHLY, 11(8 (37)), 638-645. SID. https://sid.ir/paper/306443/en

Vancouver: Copy

AHN JOSEPH, COHEN STANLEY MARTIN. PREVENTION OF HEPATITIS B RECURRENCE IN LIVER TRANSPLANT PATIENTS USING ORAL ANTIVIRAL THERAPY WITHOUT LONG-TERM HEPATITIS B IMMUNOGLOBU-LIN. HEPATITIS MONTHLY[Internet]. 2011;11(8 (37)):638-645. Available from: https://sid.ir/paper/306443/en

IEEE: Copy

JOSEPH AHN, and STANLEY MARTIN COHEN, “PREVENTION OF HEPATITIS B RECURRENCE IN LIVER TRANSPLANT PATIENTS USING ORAL ANTIVIRAL THERAPY WITHOUT LONG-TERM HEPATITIS B IMMUNOGLOBU-LIN,” HEPATITIS MONTHLY, vol. 11, no. 8 (37), pp. 638–645, 2011, [Online]. Available: https://sid.ir/paper/306443/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops